Breaking News, Collaborations & Alliances

Almac, Merck, MRC To Assess Erbitux Response Markers

Almac, Merck KGaA, and UK-based Medical Research Council (MRC), have entered into a partnership to study metastatic colorectal cancer (mCRC) using samples from the MRC COIN trial.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Almac, Merck KGaA, and UK-based Medical Research Council (MRC), have entered into a partnership to study metastatic colorectal cancer (mCRC) using samples from the MRC COIN trial. The study will assess potential biomarkers of response to cetuximab (Erbitux). Almac will use samples from the COIN trial to perform quantitative polymerase chain reaction profiling and data analysis to assess other potential biomarkers in the context of combination therapy with cetuximab. Paul Harkin, president ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters